Abstracts tagged "CPPD"

Abstract Number: 0270 • ACR Convergence 2024
Longitudinal Patterns of C-Reactive Protein Values in Calcium Pyrophosphate Deposition (CPPD) Disease
Muneet Gill, Hongshu Guan, Jamie Collins and Sara Tedeschi, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease is a crystalline arthritis affecting older adults. Systemic inflammation occurs during flares of acute calcium pyrophosphate (CPP) crystal arthritis…
Abstract Number: 0272 • ACR Convergence 2024
Calcifications of the Transverse Ligament of the Atlas in Patients Diagnosed with Calciumpyrophosphate Crystal Arthritis – a Retrospective Observational Study
Shay Brikman¹, Noga Shabshin² and Amir Bieber³, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Afula, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel
Background/Purpose: Chondrocalcinosis (CC) is commonly detected on X-ray films of the knee, wrist, and symphysis pubis. Calcium pyrophosphate (CPP) deposition disease is sometimes associated with…
Abstract Number: 0279 • ACR Convergence 2024
Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Charles Leroy¹, Nghia Pham², François Brial³, Brenda Kischkel⁴, gwénaêlle Jayat⁵, Elena Ishow⁶, Christèle Combes⁷, Leo Joosten⁴, Augustin Latourte⁸, Pascal Richette⁹ and Hang-Korng Ea¹⁰, ¹Inserm 1132 / Université Paris Cité, levallois-perret, France, ²INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, ³Inserm 1132/ Université Paris Cité, Paris, France, ⁴Radboudumc, Nijmegen, Netherlands, ⁵Université Paris cité / Inserm 1132, paris, France, ⁶Université de Nantes / Ceisam, Nantes, France, ⁷INP-ENSIACET, Toulouse, France, ⁸AP-HP, Paris, France, ⁹Lariboisière Hospital, Paris, France, ¹⁰Université Paris Cité, INSERM UMR 1132 BIOSCAR, Paris, France
Background/Purpose: Gout, due to the presence of monosodium urate crystals (MSU) and calcium pyrophosphate (CPP) crystal deposition disease are both responsible for recurrent inflammation flares.…
Abstract Number: 0284 • ACR Convergence 2024
Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
Joanna Potera¹, Angelo Gaffo², Alvin Day³, Mariana Urquiaga² and Amanda Alexander⁴, ¹University of Alabama at Birmingham, Irondale, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Dept. of Veterans Affairs, Lexington, SC, ⁴University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Calcium pyrophosphate deposition disease is a common condition that can cause chronic polyarticular inflammatory joint disease, which sometimes resembles rheumatoid arthritis. Misdiagnosis is especially…
Abstract Number: 1109 • ACR Convergence 2024
Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women
Laura Scagnellato¹, Antonio Collesei², Sonia farah³, Carlomaurizio Montecucco⁴, Francesca Oliviero⁵, Bernd raffeiner⁶, Marta favero⁵, Amelia Damasco⁵, doria Andrea⁵, Fausto Salaffi³ and Roberta Ramonda⁷, and SIR Study Group on Crystal Arthropaties, ¹Rheumatology Unit, University of Padova, Padova, Italy, ²IRCCS Istituto Oncologico Veneto IOV, Padova, Italy, ³Polytechnic University of Marche, Jesi (AN), Italy, ⁴IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ⁵University of Padova, Padova, Italy, ⁶General Hospital of Bolzano, Bolzano, Italy, ⁷Rheumatology Unit, University of Padova, Italy, Padova, Italy
Background/Purpose: Crystal arthropaties, including gout and calcium pyrophosphate deposition disease (CPPD), are prevalent and burdensome conditions. The ALLSTAR model allows the identification of reliable causal,…
Abstract Number: 1340 • ACR Convergence 2024
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Natalie Schanzer¹, Ted Mikuls², Bryant England², Katherine Wysham³, Jorge Rojas⁴, Sauer brian⁵, Beth Wallace⁶, Rachel Elam⁷, Andreas Reimold⁸, Gail Kerr⁹, John Richards¹⁰, Gary Kunkel¹¹, Iris Lee¹², Isaac Smith¹³, Paul Monach¹⁴, grant Cannon¹⁵ and Joshua Baker¹⁶, ¹Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Seattle VA, Mexico, Mexico, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷Augusta University, Evans, GA, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹²Washington University in St Louis, Saint Louis, MO, ¹³Duke University Hospital, Durham, NC, ¹⁴VA Boston Healthcare System, Boston, MA, ¹⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
Abstract Number: 2562 • ACR Convergence 2024
Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases
Sophie Carrabin¹, Margaux Houze², Charlotte Jauffret³, Thomas Bardin⁴, Hang Korng Ea⁴, Frédéric Lioté⁴, Pascal Richette⁵, Tristan Pascart² and Augustin Latourte⁶, ¹Hôpital Lariboisière APHP.Nord, Paris, Paris, France, ²Lille Catholic University, Lille, France, ³Lille Catholic University, Lille, Nord-Pas-de-Calais, France, ⁴Hôpital Lariboisière APHP.Nord, Paris, France, ⁵Lariboisière Hospital, Paris, France, ⁶AP-HP, Paris, France
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a heterogeneous disease that can manifest as acute or chronic arthritis. Treatment options for chronic forms of the…
Abstract Number: 0269 • ACR Convergence 2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Yiling Zhang¹, Sara Tedeschi², Abhishek Abhishek³, Owen Hensey⁴, David Grossberg⁵, Ken Cai⁶, Beverley Shea⁷, Jasvinder Singh⁸, Robin Christensen⁹, Teodora Serban¹⁰, Edoardo Cipolletta¹¹, Konstantinos Parperis¹², César Díaz¹³, Geraldine McCarthy¹⁴, Fabio Becce¹⁵, Tamer A Gheita¹⁶, Silvia Sirotti¹⁷, Sara Nysom Christiansen¹⁸, Luis Coronel Tarancon¹⁹, Lisa Stamp²⁰, Yousra H Abdel-Fattah²¹, Tristan Pascart²², Georgios Filippou¹⁷, Lih En Hong²³, John FitzGerald²⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Brigham and Women's Hospital, Boston, MA, ³University of Nottingham, Nottingham, United Kingdom, ⁴OMERACT patient research partner, Dublin, Ireland, ⁵OMERACT patient research partner, Maryland, ⁶Westmead Hospital, Sydney, New South Wales, Australia, ⁷Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁸Baylor College of Medicine, Birmingham, AL, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Ospedale La Colletta, Bucharest, Romania, ¹¹Polytechnic University of Marche, Ancona, Italy, ¹²University of Cyprus Medical School, Nicosia, Cyprus, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁵Lausanne University Hospital (CHUV), Lausanne, Switzerland, ¹⁶Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁷IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ¹⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ¹⁹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ²⁰University of Otago, Christchurch, Christchurch, New Zealand, ²¹Alexandria University, Alexandria, Egypt, ²²Lille Catholic University, Lille, France, ²³Royal Adelaide Hospital, Unley Park, South Australia, Australia, ²⁴UCLA, Los Angeles, CA
Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.Methods:…
Abstract Number: 0230 • ACR Convergence 2023
Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome
Sandra Ogbonnaya-Whittlesey¹, Ecem Sevim¹, Dale Kobrin¹, sarthak gupta², Paul DeMarco³ and Alexandra Freeman⁴, ¹NIH/NIAMS, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴NIH/NIAID, Bethesda, MD
Background/Purpose: Job syndrome or hyperimmunoglobulin E syndrome is an immunodeficiency for which the clinical picture consists largely of frequent infectious complications of the lungs, sinuses,…
Abstract Number: 0235 • ACR Convergence 2023
Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study
Sara Tedeschi¹, Keigo Hayashi¹, Ann Rosenthal², Javier Marrugo¹, Sho Fukui¹, Ellen Gravallese³ and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Medical College of Wisconsin, Milwaukee, WI, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease was positively associated with osteopenia in two large cross-sectional studies, but risk of fractures has not been evaluated. We…
Abstract Number: 0250 • ACR Convergence 2023
Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial Fluid
John FitzGerald¹, Tairan Liu¹, Chesca Barrios¹, Bijie Bai¹, Geraldine McCarthy², Ann Rosenthal³ and Aydogan Ozcan¹, ¹University of California Los Angeles, Los Angeles, CA, ²Mater Misericordiae University Hospital, Dublin, Ireland, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: The gold standard for diagnosis of crystal arthritis relies on the identification of either monosodium urate (MSU) or calcium pyrophosphate (CPP) crystals in synovial…
Abstract Number: 0318 • ACR Convergence 2023
The Association of CT-Detected Intra-Articular Mineralization with MRI-Detected Effusion-Synovitis and Hoffa’s Synovitis in Knee OA: The Multicenter Osteoarthritis Study
Jean Liew¹, Gabriela Rabasa¹, Mohamed Jarraya², Ali Guermazi¹, David Felson¹, Beth Lewis³, John Lynch⁴, Michael Nevitt⁴, James Torner⁵ and Tuhina Neogi⁶, ¹Boston University, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Alabama at Birimingham, Birmingham, AL, ⁴University of California San Francisco, San Francisco, CA, ⁵University of Iowa, Iowa City, IA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Intra-articular (IA) deposition of calcium crystals (chondrocalcinosis), is common in knee OA. While calcium crystals can cause inflammatory arthritis, their contribution to joint inflammation…
Abstract Number: 1115 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
Peter Mandl¹, Maria-Antonietta D'Agostino², Victoria Navarro-Compán³, Irina Gessl¹, Garifallia Sakellariou⁴, Abhishek Abhishek⁵, Fabio Becce⁶, Nicola Dalbeth⁷, Hang-Korng Ea⁸, Emilio Filippucci⁹, Hilde Berner Hammer¹⁰, Annamaria Iagnocco¹¹, Annette De Thurah¹², Esperanza Naredo¹³, Sebastien Ottaviani¹⁴, Tristan Pascart¹⁵, Fernando Perez-Ruiz¹⁶, Irene Pitsillidou¹⁷, Fabian Proft¹⁸, Juergen Rech¹⁹, Wolfgang Schmidt²⁰, Luca Sconfienza²¹, Lene Terslev²², Brigitte Wildner²³, Pascal Zufferey²⁴ and Georgios Filippou²⁵, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Universita Cattolica del Sacro Cuore Rome, Courbevoie, France, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁷University of Auckland, Auckland, New Zealand, ⁸Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, Université de Paris Cité, Paris, France, ⁹Polytechnic University of Marche, Jesi, Italy, ¹⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway AND University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹University of Turin, Roma, Italy, ¹²Aarhus University Hospital, Aarhus, Denmark, ¹³Hospital Fundación, Madrid, Spain, ¹⁴Assistance Publique Hopitaux de Paris, Paris, France, ¹⁵Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ¹⁶Rheumatology Division, Osakidetza, OSI-EE Cruces, Cruces University Hospital, Barakaldo, Spain, ¹⁷EULAR Patient Research Partner, Executive Secretary of Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁹University Clinic Erlangen, Erlangen, Germany, ²⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²¹Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano AND IRCCS Istituto Ortopedico Galeazzi, 20161, Milan, Italy, ²²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²³University Library, Medical University of Vienna, Vienna, Austria, ²⁴Rheumatology Department, University of Lausanne, CHUV, Lausenne, Switzerland, ²⁵IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Background/Purpose: The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. Our goal was to formulate evidence-based recommendations on the use of imaging…
Abstract Number: 1118 • ACR Convergence 2023
The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project
Silvia Sirotti¹, Charlotte Jauffret², Edoardo Cipolletta³, Daniele Cirillo⁴, Luca Ingrao⁴, Alessandro Lucia⁴, Antonella Adinolfi⁵, Debora Pireddu⁴, Emilio Filippucci⁶, Tristan Pascart², Sara Tedeschi⁷, Robert Terkeltaub⁸, Nicola Dalbeth⁹ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Saint-Philibert Hospital, Lille Catholic University, Lille, France, ³Polytechnic University of Marche, Ancona, Italy, ⁴Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy, ⁵Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁶Polytechnic University of Marche, Jesi, Italy, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of California San Diego, San Diego, CA, ⁹University of Auckland, Auckland, New Zealand
Background/Purpose: Despite prior attempts at standardising terminology of calcium pyrophosphate deposition (CPPD) disease (including the 2011 EULAR recommendations for CPPD terminology and diagnosis), many different…
Abstract Number: 1119 • ACR Convergence 2023
Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice
Silvia Sirotti¹, Joao Madruga-Dias², Antonella Adinolfi³, Garifallia Sakellariou⁴, Davide Rozza⁵, Greta Carrara⁵, Gianpiero Landolfi⁵, Carlo Alberto Scire⁵, Annamaria Iagnocco⁶ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Centro Hospitalar do Médio Tejo, NOVA Medical School, Lisbon, Portugal, ³Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy, ⁶University of Turin, Roma, Italy
Background/Purpose: The RADIAL study is aimed to evaluate the performance of a composite approach, based on clinical, laboratory and ultrasound (US) data in the differential…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].